<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">DIJ</journal-id>
<journal-id journal-id-type="hwp">spdij</journal-id>
<journal-title>Therapeutic Innovation &amp; Regulatory Science</journal-title>
<issn pub-type="ppub">2168-4790</issn>
<issn pub-type="epub">2164-9200</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0092861512460759</article-id>
<article-id pub-id-type="publisher-id">10.1177_0092861512460759</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Statistics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Practical Estimation Method for Analyzing Adverse Drug Reactions Using Data Mining</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shirakuni</surname>
<given-names>Yuko</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Okamoto</surname>
<given-names>Kousuke</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uejima</surname>
<given-names>Etuko</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
<xref ref-type="aff" rid="aff2-0092861512460759">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Inui</surname>
<given-names>Shigeki</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0092861512460759">3</xref>
<xref ref-type="aff" rid="aff4-0092861512460759">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Takahara</surname>
<given-names>Jun-ichi</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ohgaru</surname>
<given-names>Takanori</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
<xref ref-type="aff" rid="aff6-0092861512460759">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamasaki</surname>
<given-names>Hiroyuki</given-names>
</name>
<degrees>MPS</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
<xref ref-type="aff" rid="aff7-0092861512460759">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Yushi</given-names>
</name>
<degrees>MPS</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kawashita</surname>
<given-names>Norihito</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
<xref ref-type="aff" rid="aff5-0092861512460759">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Inoue</surname>
<given-names>Ran</given-names>
</name>
<degrees>MPS</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yasunaga</surname>
<given-names>Teruo</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff5-0092861512460759">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Takagi</surname>
<given-names>Tatsuya</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0092861512460759">1</xref>
<xref ref-type="aff" rid="aff5-0092861512460759">5</xref>
<xref ref-type="corresp" rid="corresp1-0092861512460759"/>
</contrib>
</contrib-group>
<aff id="aff1-0092861512460759"><label>1</label>Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan</aff>
<aff id="aff2-0092861512460759"><label>2</label>Department of Hospital Pharmacy Education, Osaka University, Osaka, Japan</aff>
<aff id="aff3-0092861512460759"><label>3</label>Department of Skin and Hair Regenerative Medicine, Osaka University School of Medicine, Osaka, Japan</aff>
<aff id="aff4-0092861512460759"><label>4</label>Department of Dermatology, Osaka University Hospital, Osaka, Japan</aff>
<aff id="aff5-0092861512460759"><label>5</label>Genome Information Research Center, Institute for Microbial Diseases, Osaka University, Osaka, Japan</aff>
<aff id="aff6-0092861512460759"><label>6</label>Medicinal Chemistry Research Laboratories I, Mitsubishi Tanabe Pharma Corp, Osaka, Japan</aff>
<aff id="aff7-0092861512460759"><label>7</label>Kitasato University School of Pharmacy, Tokyo, Japan</aff>
<author-notes>
<corresp id="corresp1-0092861512460759">Tatsuya Takagi, PhD, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Email: <email>ttakagi@phs.osaka-u.ac.jp</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>2</issue>
<fpage>235</fpage>
<lpage>241</lpage>
<history>
<date date-type="received">
<day>3</day>
<month>8</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="other">Drug Information Association</copyright-holder>
</permissions>
<abstract>
<p>This study aimed to determine the potentially severe chemical properties of drugs that can cause adverse drug reactions (ADRs) such as erythema multiforme (EM), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) by using a data mining method. The study data were extracted from the Adverse Event Reporting System database of the FDA. EM was considered a mild reaction, and SJS and TEN were considered severe reactions. In this study, a new concept termed the “risk of aggravation” (ROA) was defined as whether a certain drug is more likely to cause severe adverse reactions than mild ones. Partial least squares and logistic regression analysis were applied using binary response variable ROAs. These analyses correctly predicted 50 of the 72 drugs associated with SJS and/or TEN and 28 of the 38 drugs associated with EM using binary chemical descriptors that are the same as those using the metric chemical descriptors.</p>
</abstract>
<kwd-group>
<kwd>data mining</kwd>
<kwd>Stevens–Johnson syndrome</kwd>
<kwd>adverse event reporting system</kwd>
<kwd>risk of aggravation</kwd>
<kwd>partial chemical structures of drugs</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0092861512460759">
<title>Introduction</title>
<p>Since the ultimate goal of drug risk management is the appropriate and safe use of drugs, data mining is regularly used to detect such positive reactions.<sup>
<xref ref-type="bibr" rid="bibr1-0092861512460759">1</xref>
</sup> However, there is no method for identifying the risk factors of rare adverse drug reactions (ADRs). Moreover, hospitals and pharmacies cannot afford to avoid the prescription of all primary drugs suspected of ADRs. The only solution is to prescribe safer drugs that are less likely to induce severe reactions even in patients who are known to have adverse reactions.</p>
<p>The purpose of this study is to assess the risk factors of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)<sup>
<xref ref-type="bibr" rid="bibr2-0092861512460759">2</xref>
</sup> using a data mining method by coded chemical structure descriptors of drugs to provide practical and useful information for medical doctors and pharmacists.</p>
<p>In this study, we applied a data mining method to analyze the partial chemical structures of drugs as risk factors that are associated with 2 rare ADRs, SJS and TEN. Structural descriptors are useful when constructing a model for predicting ADRs. However, medical doctors and pharmacists cannot obtain these values easily in hospitals and pharmacies. Hence, these descriptors are binary coded, so that medical doctors and pharmacists can understand the structural characteristics of suspected drugs that can cause adverse reactions. Metric descriptors should be more applicable than binary ones for constructing a model for predicting ADRs because calculated descriptors contain more information than binary ones. In this study, a model with binary descriptors was assessed and compared to a model with metric descriptors.</p>
<p>Since SJS and TEN are rare and severe cutaneous ADRs of unknown etiology with high mortality rates, information about their adverse reactions is quite limited in Japan. Therefore, we used the FDA Adverse Event Reporting System (AERS) database (http://www.fda.gov/Drugs/InformationOnDrugs/ucm135151.htm) as a source of data for this study. However, because the AERS database lacks data on drugs that do not cause adverse events, it was impossible to calculate hazard ratios from the AERS data. We subsequently carried out analyses to predict the severity of such adverse events. We specifically calculated the risk ratio between the “SJS and TEN” groups and erythema multiforme (EM) after we confirmed that EM and SJS should not be classified into a same category. These ratios (hereafter referred to as the “risk of aggravation”; ROA) were used to compare the severity of EM, SJS, and TEN assuming that these conditions exist in the same spectrum. No research regarding the relationship between chemical information and the tendency to cause severe symptoms has been carried out yet. Although the complete etiologies of SJS and TEN are unknown, it is known that these adverse reactions are often induced by drugs.<sup>
<xref ref-type="bibr" rid="bibr3-0092861512460759">3</xref>
</sup>
</p>
<p>Human leukocyte antigen (HLA) is an important risk factor that can aggravate the risk of developing SJS and TEN because noncovalent interactions between a drug and an HLA complex contribute to cytotoxic T cell–mediated cell death.<sup>
<xref ref-type="bibr" rid="bibr4-0092861512460759">4</xref>
</sup> It is worth noting that if SJS and TEN are immune disorders and idiosyncratic, they must be unrelated to the effects of drugs. In contrast, phenytoin and carbamazepine increase the risk of developing SJS and TEN in patients with the HLA-B*1502 version of the HLA gene.<sup>
<xref ref-type="bibr" rid="bibr5-0092861512460759">5</xref>
</sup> It is slightly problematic that phenytoin and carbamazepine have similar chemical structures; therefore, we assessed the ability of the structure–activity relationship model<sup>
<xref ref-type="bibr" rid="bibr6-0092861512460759">6</xref>
</sup> to predict ROAs on the basis of the partial chemical structures of drugs.</p>
</sec>
<sec id="section2-0092861512460759" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>We calculated the ratio between the number of severe and mild cases of SJS and TEN to determine the ROA of each primary suspect drug. Partial least squares (PLS) and logistic regression analysis (LRA) were applied to analyzing response variables, ROAs.</p>
<p>Data sets were constructed from files in the AERS database by using Microsoft Office Access 2003. Statistical analyses were performed using the <italic>R</italic> software package (versions 2.3.1 and 2.7.2).</p>
<sec id="section3-0092861512460759">
<title>Data Sets</title>
<p>We used the publicly available 2004 AERS database to construct data sets. The 7 file types included in the AERS database are named DEMOGRAPHIC (238,332 reports), DRUG (238,332 reports), REACTION (238332 reports), OUTCOME (173,184 reports), REPORT SOURCE (163,505 reports), THERAPY DATE (163,890 reports), and INDICATION FOR USE (187,453 reports). First, we retrieved patient data from the REACTION files by using the keywords <italic>TEN</italic>, <italic>SJS</italic>, and <italic>EM</italic>. Here, let EM be a milder ADRs than the other 2. When 2 or more symptoms were reported by a single patient, the most severe symptom was selected as the characteristic symptom to avoid false negatives.</p>
<p>Next, we extracted the data for drug candidates that may cause TEN, SJS, or EM from the DRUG files. In the database, these drugs were classified into 4 groups: primary suspect (PS), secondary suspect (SS), concomitant (C), and interacting (I) drugs. In this study, we only focused on PS drugs. Since the drug nomenclature in the DRUG files was not uniform, we translated all the drugs selected for our analyses into their generic names using the FDA drug dictionary (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm). Drugs that were not listed in the dictionary were instead identified from their manufacturers’ websites. In total, we selected 971 drugs for our analyses. To include as many drugs as possible in the data set, we did not consider the method of drug delivery.</p>
<p>We subsequently obtained the chemical structures of the drugs in the Molecular Design Limited (MDL) mol file format from either the Drug Bank database (http://www.drugbank.ca/) or the Japan Chemical Substance Dictionary Web Service (http://nikkajiweb.jst.go.jp/nikkaji_web/pages/top.html). We were able to obtain 110 drugs’ MDL mol files. We subsequently used the Molecular Operating Environment software (version 2006.8; Chemical Computing Group, Inc., Montreal, Canada) to replace these files with their Molecular Access System key (called structural descriptors), which is a representation of the 2D chemical structure of a drug.<sup>
<xref ref-type="bibr" rid="bibr7-0092861512460759">7</xref>
</sup> Structural descriptors are expressed numerically to create the data for the structural aspects and physicochemical profiles of a given compound, which can be utilized for computational analysis.</p>
<p>We generated 4 data sets for PS drugs with 2 types of predictor variables and 2 sets of response variables (<xref ref-type="table" rid="table1-0092861512460759">Table 1</xref>). The 2 types of predictor variables were named “binary” and “metric.” Binary variables were adopted to indicate the presence (= 1) or absence (= 0) of particular chemical structure groups in drugs that can induce EM, SJS, or TEN. Metric variables were adopted to indicate the number of chemical structure groups contained in a particular drug. Due to the ambiguity in the diagnostic criteria for EM, SJS, and TEN, we combined the SJS response variable with that of either EM or TEN for analysis. As a result, 1 set of response variables comprised EM+SJS and TEN, whereas the other set consisted of EM and SJS+TEN.</p>
<table-wrap id="table1-0092861512460759" position="float">
<label>Table 1.</label>
<caption>
<p>Predictor and Response Variables in the 4 Data Sets.</p>
</caption>
<graphic alternate-form-of="table1-0092861512460759" xlink:href="10.1177_0092861512460759-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Data Set</th>
<th> </th>
<th colspan="2"> Response Variables</th>
</tr>
<tr>
<th>Type of Predictor Variable</th>
<th>Code = 0 </th>
<th>Code = 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Binary<sup>a</sup>
</td>
<td>EM+SJS<sup>a</sup> (n = 107)</td>
<td> TEN<sup>a</sup> (n = 107)</td>
</tr>
<tr>
<td>2</td>
<td>Binary</td>
<td> EM (n = 38)</td>
<td>SJS+TEN (n = 72)</td>
</tr>
<tr>
<td>3</td>
<td>Metric<sup>b</sup>
</td>
<td>EM+SJS (n = 107)</td>
<td> TEN (n = 107)</td>
</tr>
<tr>
<td>4</td>
<td>Metric</td>
<td> EM (n = 38)</td>
<td>SJS+TEN (n = 72)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0092861512460759">
<p>EM, erythema multiforme; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.</p>
</fn>
<fn id="table-fn2-0092861512460759">
<p>
<sup>a</sup>Predictor variables representing the presence or absence of chemical structures in a drug.</p>
</fn>
<fn id="table-fn3-0092861512460759">
<p>
<sup>b</sup>Predictor variables representing the number of chemical structures in a drug.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0092861512460759">
<title>Application of PLS and LRA</title>
<p>We used PLS regression analysis<sup>
<xref ref-type="bibr" rid="bibr8-0092861512460759">8</xref>
</sup> to reduce the dimensionality of a data set and remove multicollinearity. We subsequently employed LRA<sup>
<xref ref-type="bibr" rid="bibr9-0092861512460759">9</xref>
</sup> to build a model for estimating the occurrence of adverse reactions of EM, SJS, and TEN and for calculating odds ratios. In addition, we evaluated the fitness and adaptability of the model by 10-fold cross-validation and the percentage of correct predictions, respectively. Since EM, SJS, and TEN are relatively rare, the number of samples that could be prepared was lesser than the number of predictor variables; the excess of predictor variables caused multicollinearity. In the case of the PLS, a model was built using latent variables matrix, <bold>T</bold>, shown in equations <xref ref-type="disp-formula" rid="disp-formula1-0092861512460759">1</xref> and <xref ref-type="disp-formula" rid="disp-formula2-0092861512460759">2</xref>, where <bold>P</bold> is the loading matrix; <bold>E </bold>and<bold> f </bold>are residual error matrix and vector, respectively; <bold>q </bold>and <bold>b </bold>are the regression coefficients vectors. The PLS model was shown in <xref ref-type="disp-formula" rid="disp-formula3-0092861512460759">equation 3</xref>.<disp-formula id="disp-formula1-0092861512460759">
<label>1</label>
<mml:math id="mml-disp1-0092861512460759">
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">P</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">+</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">E</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0092861512460759" xlink:href="10.1177_0092861512460759-eq1.tif"/>
</disp-formula>
<disp-formula id="disp-formula2-0092861512460759">
<label>2</label>
<mml:math id="mml-disp2-0092861512460759">
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">y</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">q</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mi mathvariant="normal">f</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0092861512460759" xlink:href="10.1177_0092861512460759-eq2.tif"/>
</disp-formula>
<disp-formula id="disp-formula3-0092861512460759">
<label>3</label>
<mml:math id="mml-disp3-0092861512460759">
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">y</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0092861512460759" xlink:href="10.1177_0092861512460759-eq3.tif"/>
</disp-formula>
</p>
<p>Four data sets were prepared as shown in <xref ref-type="table" rid="table1-0092861512460759">Table 1</xref>. Because we would like to obtain the better model, the prepared 4 data sets consisted of 2 factors: one is the predictor variables “binary” and “metric,” and the other is the severer symptoms “TEN” and “SJS+TEN”. In addition, because the response variable for PLS had to be continuous rather than discrete, we calculated a continuous response variable, <bold>Y</bold>, using PLS (<xref ref-type="disp-formula" rid="disp-formula4-0092861512460759">equation 4</xref>) that was based on the number of reports for a drug in EM, SJS, and TEN.<disp-formula id="disp-formula4-0092861512460759">
<label>4</label>
<mml:math id="mml-disp4-0092861512460759">
<mml:msub>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="bold">Y</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">P</mml:mi>
<mml:mi mathvariant="normal">L</mml:mi>
<mml:mi mathvariant="normal">S</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">=</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">N</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">N</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
</mml:mrow>
</mml:mrow>
<mml:munder>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">S</mml:mi>
<mml:mi mathvariant="normal">J</mml:mi>
<mml:mi mathvariant="normal">S</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mi mathvariant="normal">T</mml:mi>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">N</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo accent="true" stretchy="true">_</mml:mo>
</mml:munder>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">N</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">m</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
</mml:mrow>
</mml:mrow>
<mml:munder>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">S</mml:mi>
<mml:mi mathvariant="normal">J</mml:mi>
<mml:mi mathvariant="normal">S</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mo accent="true" stretchy="true">_</mml:mo>
</mml:munder>
<mml:mtext> </mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">E</mml:mi>
<mml:mi mathvariant="normal">M</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0092861512460759" xlink:href="10.1177_0092861512460759-eq4.tif"/>
</disp-formula>
</p>
<p>Since drugs with a denominator of zero in <xref ref-type="disp-formula" rid="disp-formula4-0092861512460759">equation 4</xref> have simple syndromes, their ADRs do not tend to progress from mild to severe. Thus, if the denominator for a drug was zero, the drug was excluded from the data set. In addition, we excluded the predictor variables that had variances less than 0.05. Each variable was standardized with mean = 0 and variance = 1.</p>
<p>To calculate the scores of the components for the predictor variables of LRA, we evaluated the coefficients of determination (<italic>R</italic>
<sup>2</sup>)<sup>
<xref ref-type="bibr" rid="bibr10-0092861512460759">10</xref>
</sup> and the cumulative contributions from the descriptors of the PLS results. The PLS model was considered to be inappropriate when <italic>R</italic>
<sup>2</sup> &lt; 0.7, even if the cumulative contribution of latent variables was 100%. We applied LRA only to the data sets with appropriate PLS models.</p>
<p>The selection criterion for the predictor variables in LRA was <italic>R</italic>
<sup>2</sup> &gt; 0.7 in the PLS regression analysis. If <bold>Y</bold>
<sub>PLS</sub> ≥ 1 for a drug, then <bold>Y</bold>
<sub>LRA</sub> = 1; otherwise, <bold>Y</bold>
<sub>LRA</sub> = 0 (<bold>Y</bold>
<sub>LRA</sub> is the response variable). Consequently, each LRA variable was standardized with mean = 0 and variance = 1 as in the PLS regression analysis. Next, we obtained the optimized model by stepwise variable selections based on the lowest Akaike’s information criterion<sup>
<xref ref-type="bibr" rid="bibr11-0092861512460759">11</xref>
</sup> in the LRA. The reliability of the LRA results was evaluated according to the <italic>P</italic> values; a result was considered statistically significant if <italic>P</italic> ≤ .1. In addition, the fitness of the model was determined with 10-fold cross-validation. In this procedure, the mean square error (MSE; <xref ref-type="disp-formula" rid="disp-formula5-0092861512460759">equation 5</xref>) was calculated as follows,<disp-formula id="disp-formula5-0092861512460759">
<label>5</label>
<mml:math id="mml-disp5-0092861512460759">
<mml:mi>M</mml:mi>
<mml:mi>S</mml:mi>
<mml:mi>E</mml:mi>
<mml:mo stretchy="false">=</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mn>1</mml:mn>
<mml:mi>n</mml:mi>
</mml:mfrac>
</mml:mrow>
<mml:mrow>
<mml:munderover>
<mml:mo movablelimits="false" stretchy="false">∑</mml:mo>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mi>n</mml:mi>
</mml:munderover>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mfenced close=")" open="(">
<mml:mrow>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">b</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">,</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">−</mml:mo>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mi mathvariant="normal">d</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">,</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfenced>
<mml:mn>2</mml:mn>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0092861512460759" xlink:href="10.1177_0092861512460759-eq5.tif"/>
</disp-formula>
</p>
<p>where <italic>y</italic>
<sub>obs,<italic>i</italic>
</sub> and <italic>y</italic>
<sub>pred,<italic>i</italic>
</sub> are the <italic>i</italic>th (<italic>i</italic> = 1, 2,…, <italic>n</italic>) observed and predicted values, respectively. In this study, the MSEs of 2 models using binary and metric predictor variables were assessed. Even if one model can classify the ADRs and the model’s MSE is much larger than the one of the other, we considered the former model to be insufficient. The 10-fold cross-validation was repeated 50 times. Finally, if the predicted probabilities from the estimated model were &gt; 0.5 for a drug, we considered it likely to cause SJS and TEN, or TEN alone; otherwise, we considered that it was likely to cause EM, or EM and SJS.</p>
</sec>
</sec>
<sec id="section5-0092861512460759">
<title>Results</title>
<p>The data set used in this study consisted of 315, 748, and 415 cases of EM, SJS, and TEN, respectively, from the REACTION files, and 438, 672, and 596 drugs for EM, SJS, and TEN, respectively, from the DRUG files in the AERS database. We selected the most serious symptoms of any patient who was treated with drugs for 2 or 3 symptoms. Finally, the data set used to predict the relationship between the chemical structures of the drugs and the ROA of EM, SJS, or TEN comprised 110 drugs (72 drugs for SJS or TEN) and 115 (for the binary predictor variables) or 116 (for the metric predictor variables) structural descriptors. In the data sets with EM+SJS and TEN response variables (data sets 1 and 3 in <xref ref-type="table" rid="table1-0092861512460759">Table 1</xref>), we used 127 predictor variables that had variances exceeding 0.05. Similarly, in the data sets with EM and SJS+TEN response variables (data sets 2 and 4 in <xref ref-type="table" rid="table1-0092861512460759">Table 1</xref>), we used 115 binary predictor variables and 116 metric variables that had variances exceeding 0.05. The models for data sets 2 and 4 were considered appropriate because their <italic>R</italic>
<sup>2</sup> values were greater than 0.7. In contrast, the models for data sets 1 and 3 were not appropriate even when the cumulative contributions of components reached 100% (data not shown) because their <italic>R</italic>
<sup>2</sup> values were less than 0.7. Root mean square error of prediction (RMSEP) was considered to be inappropriate for the model selections in this study because the optimum model indicated much lower <italic>R</italic>
<sup>2</sup> when RMSEP was used as an optimizer. As a result, building PLS regression models was insufficient because they could not discriminate between EM+SJS and TEN in data sets 1 and 3. The models with only 1 component had the lowest root MSEs of prediction. However, since our purpose for using PLS regression was to minimize the dimensionality of the data set and maximize information extraction, we determined the optimal number of components for the model based on the <italic>R</italic>
<sup>2</sup> values. As a result, we used only 7 and 8 components in the models for data sets 2 and 4, respectively, to satisfy the condition that <italic>R</italic>
<sup>2</sup> &gt; 0.7. Thus, using PLS regression, the 115 or 116 predictor variables in data sets 2 and 4 could be reduced to only 7 and 8 latent variables in <xref ref-type="table" rid="table2-0092861512460759">Table 2</xref>, respectively.</p>
<table-wrap id="table2-0092861512460759" position="float">
<label>Table 2.</label>
<caption>
<p>
<italic>R</italic>
<sup>2</sup> Cumulative Contribution of Components and RMSEP in the PLS Models.</p>
</caption>
<graphic alternate-form-of="table2-0092861512460759" xlink:href="10.1177_0092861512460759-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Number of Components in the PLS Model</th>
<th colspan="3">Data Set 2</th>
<th colspan="3">Data Set 4</th>
</tr>
<tr>
<th>Cumulative Contribution of Components (%)</th>
<th>Determination Coefficient (<italic>R</italic>
<sup>2</sup>)</th>
<th>RMSEP</th>
<th>Cumulative Contribution of Components (%)</th>
<th>Determination Coefficient (<italic>R</italic>
<sup>2</sup>)</th>
<th>RMSEP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10.2</td>
<td>0.190</td>
<td>1.02</td>
<td>11.5</td>
<td>0.176</td>
<td>3.32</td>
</tr>
<tr>
<td>2</td>
<td>16.4</td>
<td>0.335</td>
<td>1.12</td>
<td>23.0</td>
<td>0.293</td>
<td>3.43</td>
</tr>
<tr>
<td>3</td>
<td>21.4</td>
<td>0.474</td>
<td>1.20</td>
<td>31.3</td>
<td>0.388</td>
<td>3.42</td>
</tr>
<tr>
<td>4</td>
<td>26.6</td>
<td>0.556</td>
<td>1.24</td>
<td>36.6</td>
<td>0.494</td>
<td>3.48</td>
</tr>
<tr>
<td>5</td>
<td>29.2</td>
<td>0.634</td>
<td>1.25</td>
<td>41.0</td>
<td>0.568</td>
<td>3.52</td>
</tr>
<tr>
<td>6</td>
<td>32.1</td>
<td>0.685</td>
<td>1.28</td>
<td>45.8</td>
<td>0.615</td>
<td>3.53</td>
</tr>
<tr>
<td>7</td>
<td>35.6</td>
<td>0.721</td>
<td>1.33</td>
<td>49.2</td>
<td>0.669</td>
<td>3.51</td>
</tr>
<tr>
<td>8</td>
<td>38.7</td>
<td>0.754</td>
<td>1.36</td>
<td>52.3</td>
<td>0.702</td>
<td>3.54</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0092861512460759">
<p>PLS, partial least squares; RMSEP, root mean square error of prediction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The probabilities of correctly predicting the adverse reactions associated with these drugs in data sets 2 and 4 are shown in <xref ref-type="table" rid="table3-0092861512460759">Table 3</xref>. Specifically, 50 out of 72 drugs (69.4%) were correctly predicted as having higher ROAs, whereas 28 out of 38 drugs (73.7%) were correctly predicted as having lower ROAs. As shown in <xref ref-type="table" rid="table3-0092861512460759">Table 3</xref>, the predictive accuracy of the model with binary predictor variables representing the partial chemical structures of PS drugs was not significantly different from that of the model with the metric predictor variables.</p>
<table-wrap id="table3-0092861512460759" position="float">
<label>Table 3.</label>
<caption>
<p>Predicted Probabilities of Stevens–Johnson Syndrome + Toxic Epidermal Necrolysis With Erythema Multiforme in Data Sets 2 and 4.</p>
</caption>
<graphic alternate-form-of="table3-0092861512460759" xlink:href="10.1177_0092861512460759-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="2">Predicted</th>
<th colspan="2" rowspan="2">Prediction Accuracy (%)</th>
</tr>
<tr>
<th>
</th>
<th>SJS+TEN</th>
<th>EM</th>
</tr>
</thead>
<tbody>
<tr>
<td>SJS+TEN</td>
<td>50</td>
<td>22</td>
<td>69.4</td>
<td rowspan="2">70.9<sup>a</sup>
</td>
</tr>
<tr>
<td>EM</td>
<td>10</td>
<td>28</td>
<td>73.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0092861512460759">
<p>EM, erythema multiforme; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.</p>
</fn>
<fn id="table-fn6-0092861512460759">
<p>
<sup>a</sup>Predictive accuracy of all drugs.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The differences between the MSEs of data sets 2 and 4 were similar: 0.192-0.196 and 0.196-0.200, respectively. In addition, both types of predictor variables were able to predict the ROA quite accurately. The regression coefficients for the 40 predictor variables used to predict the ROAs of data sets 2 and 4 are shown in <xref ref-type="table" rid="table4-0092861512460759">Tables 4</xref> and <xref ref-type="table" rid="table5-0092861512460759">5</xref>, respectively. These regression coefficients indicate that heavy atom–(aromatic atom)<sup>
<xref ref-type="bibr" rid="bibr2-0092861512460759">2</xref>
</sup>–heavy atom, chlorine atoms, and various types of bonds between hetero atoms in the chemical structures of drugs were associated with higher ROAs. In contrast, aliphatic structures were associated with lower ROAs. We analyzed antibacterial drugs, nonsteroidal antiinflammatory drugs (NSAIDs), neurologic drugs, cardiovascular drugs, drugs for gout treatment, gastric drugs, and so on as the drugs suspected to cause SJS/TEN. These drugs contain the descriptors indicating the largest regression coefficients (atoms separated by (!:):(!:)) as shown in <xref ref-type="table" rid="table4-0092861512460759">Tables 4</xref> and <xref ref-type="table" rid="table5-0092861512460759">5</xref>. Furthermore, such chemical structures associated with higher ROA are included in a few drugs that are not suspected to cause SJS/TEN. Psychiatric drugs in particular may be suspected to cause SJS/TEN.</p>
<table-wrap id="table4-0092861512460759" position="float">
<label>Table 4.</label>
<caption>
<p>Regression Coefficients Predicting the Risk of Aggravation With Binary Predictors.</p>
</caption>
<graphic alternate-form-of="table4-0092861512460759" xlink:href="10.1177_0092861512460759-table4.tif"/>
<table>
<thead>
<tr>
<th>Characteristics of Partial Structures</th>
<th>Regression Coefficient</th>
<th>Characteristics of Partial Structures</th>
<th>Regression Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atoms separated by (!:):(!:)<sup>a</sup>
</td>
<td>0.2556 </td>
<td>N in C–N single bonds</td>
<td>–0.3032 </td>
</tr>
<tr>
<td>X separated by (!r)-r-(!r)<sup>b,c</sup>
</td>
<td>0.2333 </td>
<td>N with coordination number ≥ 3</td>
<td>–0.2858 </td>
</tr>
<tr>
<td>N bonded to O</td>
<td>0.2277 </td>
<td>N bonded to ≥ 3 C</td>
<td>–0.2702 </td>
</tr>
<tr>
<td>Halogens bonded to any ring</td>
<td>0.1761 </td>
<td>O attached to CH<sub>2</sub>
</td>
<td>–0.2607 </td>
</tr>
<tr>
<td>N bonded to non C</td>
<td>0.1717 </td>
<td>X-H heteroatoms 2 bonds from another<sup>b</sup>
</td>
<td>–0.2519 </td>
</tr>
<tr>
<td>O separated by 1 C</td>
<td>0.1613 </td>
<td>N nonring bonded to a ring</td>
<td>–0.2456 </td>
</tr>
<tr>
<td>XQ &gt; 3 bonded to at least 1 halogen<sup>d</sup>
</td>
<td>0.1609 </td>
<td>Non-C with coordination number ≥ 3</td>
<td>–0.2444 </td>
</tr>
<tr>
<td>C bonded to ≥ 2 C and 1 O</td>
<td>0.1606 </td>
<td>XCH<sub>2</sub>X, where X&lt;&gt;C</td>
<td>–0.2083 </td>
</tr>
<tr>
<td>Chlorine atoms</td>
<td>0.1472 </td>
<td>N double-bonded to C</td>
<td>–0.2052 </td>
</tr>
<tr>
<td>Aromatics</td>
<td>0.1416 </td>
<td>CH<sub>2</sub> attached to CH<sub>2</sub>
</td>
<td>–0.1961 </td>
</tr>
<tr>
<td>Halogens</td>
<td>0.1409 </td>
<td>N attached to CH<sub>2</sub>
</td>
<td>–0.1941 </td>
</tr>
<tr>
<td>Het–het bonds</td>
<td>0.1068 </td>
<td>N 2 bonds from a CH<sub>2</sub>
</td>
<td>–0.1938 </td>
</tr>
<tr>
<td>S bonded to a C and an O</td>
<td>0.1063 </td>
<td>CH3 2 bonds from a CH<sub>2</sub>
</td>
<td>–0.1907 </td>
</tr>
<tr>
<td>Iodine atoms</td>
<td>0.1039 </td>
<td>S atoms in rings</td>
<td>–0.1822 </td>
</tr>
<tr>
<td>O in nonaromatic bonds to an [a]</td>
<td>0.1031 </td>
<td>O 1 C from an N</td>
<td>–0.1745 </td>
</tr>
<tr>
<td>N bonded to N</td>
<td>0.1004 </td>
<td>C bonded to ≥ 1 N, ≥ 1 C, &amp; ≥ 1 O</td>
<td>–0.1666 </td>
</tr>
<tr>
<td> Oxygen atoms &gt; 2</td>
<td>0.0976 </td>
<td>N in rings</td>
<td>–0.1662 </td>
</tr>
<tr>
<td>N bonded to 2 non-C heavy atoms</td>
<td>0.0956 </td>
<td>CH<sub>2</sub> or CH<sub>3</sub> separated by non-C atoms</td>
<td>–0.1659 </td>
</tr>
<tr>
<td>S bonded to an N and a C</td>
<td>0.0904 </td>
<td>Noncarbons attached to CH<sub>2</sub>
</td>
<td>–0.1656 </td>
</tr>
<tr>
<td>NH<sub>2</sub> groups</td>
<td>0.0896 </td>
<td>N 2 bonds from an O</td>
<td>–0.1619 </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0092861512460759">
<p>
<sup>a</sup>Heavy atom–(aromatic atom)<sup>
<xref ref-type="bibr" rid="bibr2-0092861512460759">2</xref>
</sup>–heavy atom.</p>
</fn>
<fn id="table-fn8-0092861512460759">
<p>
<sup>b</sup>X indicates a noncarbon or nonhydrogen atom.</p>
</fn>
<fn id="table-fn9-0092861512460759">
<p>
<sup>c</sup>r indicates an atom in a ring.</p>
</fn>
<fn id="table-fn10-0092861512460759">
<p>
<sup>d</sup>Q indicates a heavy atom.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0092861512460759" position="float">
<label>Table 5.</label>
<caption>
<p>Regression Coefficients for Predicting the Risk of Association With Metric Predictors.</p>
</caption>
<graphic alternate-form-of="table5-0092861512460759" xlink:href="10.1177_0092861512460759-table5.tif"/>
<table>
<thead>
<tr>
<th>Characteristics of Partial Structures</th>
<th>Regression Coefficient</th>
<th>Characteristics of Partial Structures</th>
<th>Regression Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atoms separated by (!:):(!:)<sup>a</sup>
</td>
<td>0.3725 </td>
<td>O attached to ch<sub>2</sub>
</td>
<td>–0.2765 </td>
</tr>
<tr>
<td>N in a nonaromatic bond with [a]</td>
<td>0.3097 </td>
<td>XCH<sub>2</sub>X, where X&lt;&gt;C</td>
<td>–0.2200 </td>
</tr>
<tr>
<td>N nonring bonded to a ring<sup>b</sup>
</td>
<td>0.2996 </td>
<td>X-H heteroatoms 2 bonds from another atom<sup>c</sup>
</td>
<td>–0.2127 </td>
</tr>
<tr>
<td>Atoms in 3 ring</td>
<td>0.2303 </td>
<td>N in double bonds</td>
<td>–0.1660 </td>
</tr>
<tr>
<td>Heteroatoms in a 6 ring</td>
<td>0.2030 </td>
<td>C in C=C</td>
<td>–0.1654 </td>
</tr>
<tr>
<td>C bonded to at least 3 N atoms</td>
<td>0.1574 </td>
<td>Fluorine atoms</td>
<td>–0.1630 </td>
</tr>
<tr>
<td>S bonded to an N and a C</td>
<td>0.1497 </td>
<td>C in C=C bonded to ≥ 3 C</td>
<td>–0.1545 </td>
</tr>
<tr>
<td>Nonring bonds that connect rings</td>
<td>0.1495 </td>
<td>C in C=C bonded to ≥ 3 heavy atoms</td>
<td>–0.1532 </td>
</tr>
<tr>
<td>Halogens bonded to any ring</td>
<td>0.1435 </td>
<td>Dimethyl substituted atoms</td>
<td>–0.1497 </td>
</tr>
<tr>
<td>Chlorine atoms</td>
<td>0.1429 </td>
<td>N atoms in double bonds with O</td>
<td>–0.1490 </td>
</tr>
<tr>
<td>Methylated heteroatoms</td>
<td>0.1326 </td>
<td>O<sub>2</sub> bonds from CH<sub>2</sub>
</td>
<td>–0.1440 </td>
</tr>
<tr>
<td>X separated by (!R)-r-(!R)<sup>c,d</sup>
</td>
<td>0.1280 </td>
<td>Noncarbons attached to CH<sub>2</sub>
</td>
<td>–0.1393 </td>
</tr>
<tr>
<td>N bonded to non C</td>
<td>0.1256 </td>
<td>C in 3-ring bonds and a double bond</td>
<td>–0.1378 </td>
</tr>
<tr>
<td>Aromatic ring &gt; 1?</td>
<td>0.1207 </td>
<td>Heteroatoms attached to a CH<sub>2</sub>
</td>
<td>–0.1277 </td>
</tr>
<tr>
<td>S bonded to ≥ 2 O</td>
<td>0.1206 </td>
<td>OH groups</td>
<td>–0.1254 </td>
</tr>
<tr>
<td>Nonring S attached to a ring</td>
<td>0.1128 </td>
<td>CH<sub>2</sub> attached to CH<sub>2</sub>
</td>
<td>–0.1222 </td>
</tr>
<tr>
<td>N bonded to N</td>
<td>0.1128 </td>
<td>Nonring CH<sub>2</sub>
</td>
<td>–0.1160 </td>
</tr>
<tr>
<td>S bonded to a C and an O</td>
<td>0.0979 </td>
<td>Het atoms with H</td>
<td>–0.1101 </td>
</tr>
<tr>
<td>S attached to Q ≥ 3 atoms<sup>e</sup>
</td>
<td>0.0882 </td>
<td>N double bonded to C</td>
<td>–0.1099 </td>
</tr>
<tr>
<td>N nonring bonded to a ring (2)<sup>f</sup>
</td>
<td>0.0867 </td>
<td>Hets. 2 bonds from a CH<sub>2</sub>
</td>
<td>–0.1071 </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0092861512460759">
<p>
<sup>a</sup>Heavy atom–(aromatic atom)<sup>
<xref ref-type="bibr" rid="bibr2-0092861512460759">2</xref>
</sup>–heavy atom.</p>
</fn>
<fn id="table-fn12-0092861512460759">
<p>
<sup>b</sup>N nonring bonded to a ring (1) indicates N-(nonring bonded)-Q-(ring bonded)-Q.</p>
</fn>
<fn id="table-fn13-0092861512460759">
<p>
<sup>c</sup>X indicates a noncarbon or nonhydrogen atom.</p>
</fn>
<fn id="table-fn14-0092861512460759">
<p>
<sup>d</sup>r indicates an atom in a ring.</p>
</fn>
<fn id="table-fn15-0092861512460759">
<p>
<sup>e</sup>Q indicates a heavy atom.</p>
</fn>
<fn id="table-fn16-0092861512460759">
<p>
<sup>f</sup>N nonring bonded to a ring (2) indicates Q-(nonring bonded)-N-(ring bonded)-Q.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>These results for MSEs and regression coefficients suggest that the quality of the model with binary predictor variables is acceptable. Moreover, the most important results of these analyses are that therapeutic categories of drugs are insufficient for estimating ROA.</p>
</sec>
<sec id="section6-0092861512460759">
<title>Discussion</title>
<p>In general, the fatality rates related to SJS and TEN are approximately 10% and 30%, respectively, whereas that of EM is particularly low.<sup>
<xref ref-type="bibr" rid="bibr12-0092861512460759">12</xref>
</sup> However, there are different criteria for these conditions. For example, the Pharmaceuticals and Medical Devices Safety Information No. 163 (http://www1.mhlw.go.jp/houdou/1211/h1130-1_a_15.html) states that EM major and SJS have the same cutaneous symptoms. In contrast, the National Organization for Rare Disorders (http://www.rarediseases.org/) defines the symptoms of SJS and TEN as more severe than those of EM. Auquier-Dunant et al<sup>
<xref ref-type="bibr" rid="bibr13-0092861512460759">13</xref>
</sup> suggest additional terms, namely “EM-SJS overlap” and “SJS-TEN overlap,” to classify the cases in which the clinical symptoms cover more than 1 disease. In addition, they conclude that EM major differs from SJS and TEN, not only with respect to the severity of symptoms but also with regard to several demographic characteristics and etiologies. Moreover, in the case of our data, the confusion regarding the names of symptoms was clarified using data sets 2 and 4. In data sets 2 and 4, 2 types of predictor variables that indicate the chemical characteristics of drugs were compared by their ability to predict the possibilities of becoming adverse reaction severer. Therefore, we introduced the concept of ROA in this study. Signal detection is a data mining method that is utilized for early prediction of ADRs. The proportional reporting ratio is commonly used by the Medicines and Healthcare Products Regulatory Agency (MHRA), while the FDA uses the Gamma-Poisson Shrinker Program for predicting ADRs. In addition, the World Health Organization uses the Bayesian confidence propagation neural network. The response variable of signal detection indicates the development of disease. The ROA used in this study is a new quantitative variable that can be predicted by the partial chemical structures of drugs according to the verification outcome of the SJS and TEN groups. Specifically, we applied the models using the structural descriptors of drugs related to SJS, TEN, and EM to predict their ROAs. Since the predictor variables for these structural representations of drugs have multicollinearities, we used PLS regression to construct the models of the 4 data sets (<xref ref-type="table" rid="table1-0092861512460759">Table 1</xref>). PLS is a reasonable method for this study because the amount of data we have is insufficient for ordinal multiple regression or logistic regression methods, considering that many predictive variables could be used. The response variable of the PLS method is subjected to regression by latent variables, which are prepared using linear combinations of some predictive variables. The PLS method is advantageous for rare and unexplained diseases because it enables the use of many descriptors. The combination of PLS and LRA is problematic in that Y<sub>PLS</sub> is metric and Y<sub>LRA</sub> is binary. However, we did not mention this because our purpose was comparing the ability between the model with binary predictor variables and that with metric ones.</p>
<p>These models indicate that SJS and TEN have similar symptoms, and that patients with SJS and/or TEN should be differentiated from those with EM. Although the spread of the 50 MSEs from data set 2 was slightly smaller than that of data set 4, data set 2 seemed to have slightly more accurate predictive ability. However, both models exhibited similarly good fit. Since it is often difficult to diagnose TEN and SJS correctly in clinical settings, we propose that EM rather than SJS should be used as a control. The drug categories that are most frequently reported as candidates associated with SJS and TEN include antibacterial drugs, NSAIDs, neurologic drugs, cardiovascular drugs, drugs for gout treatment, and gastric drugs. However, the obtained important partial structures associated with SJS and TEN were observed in many different drug categories. Thus, the procedure with the binary predictor variables described in the present study is potentially clinically applicable for predicting which drugs have high risks for progressing to SJS/TEN from EM.</p>
<p>In conclusion, we predicted the ROA of drugs by analysis using descriptors indicating the presence of special chemical structures; the descriptors were associated with the progression from mild to severe symptoms of ADRs in the case of EM, SJS, and TEN. The prediction model with binary predictor variables for SJS and TEN was reasonable. Using this model may enable medical doctors and pharmacists to prescribe safer drugs. Our future research will aim at analyzing the personal risk, probability of occurrence, and degree of influence of side effects in patients.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0092861512460759">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0092861512460759">
<label>Funding</label>
<p>This work was funded by a grant-in-aid for scientific research (C) (21590157). </p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0092861512460759">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsunenari</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Barata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Establishment of drug risk management system—the promise of safety science approaching from non-clinical safety</article-title>. <source>Jpn J Pharmacoepidemiol</source>. <year>2008</year>;<volume>13</volume>:<fpage>29</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr2-0092861512460759">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roujeau</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Naldi</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis</article-title>. <source>N Engl J Med</source>. <year>1995</year>:<volume>333</volume>(<issue>24</issue>):<fpage>1600</fpage>–<lpage>1607</lpage>.</citation>
</ref>
<ref id="bibr3-0092861512460759">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mockenhaupt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Viobud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dunant</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study</article-title>. <source>J Invest Dermatol</source>. <year>2003</year>;<volume>128</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr4-0092861512460759">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
</person-group> <article-title>Harvesting candidate genes responsible for serious ADRs from a chemical-protein interactome</article-title>. <source>PloS Comput Biol</source>. <year>2009</year>;<volume>5</volume>(<issue>7</issue>):<fpage>e1000441</fpage>.</citation>
</ref>
<ref id="bibr5-0092861512460759">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Locharernkul</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Loplumlert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Limotai</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population</article-title>. <source>Epilepsia</source>. <year>2008</year>;<volume>49</volume>(<issue>12</issue>):<fpage>2087</fpage>–<lpage>2091</lpage>.</citation>
</ref>
<ref id="bibr6-0092861512460759">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKinney</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gerberick</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>The practice of structure activity relationships (SAR) in toxicology</article-title>. <source>Toxicol Sci</source>. <year>2000</year>;<volume>56</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr7-0092861512460759">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckert</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bajorath</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Design and evaluation of a novel class-directed 2D fingerprint to search for structurally diverse active compounds</article-title>. <source>J Chem Inf Model</source>. <year>2006</year>;<volume>46</volume>(<issue>6</issue>):<fpage>2515</fpage>–<lpage>2526</lpage>.</citation>
</ref>
<ref id="bibr8-0092861512460759">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiromatsu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takahara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nishihara</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Prediction for biodegradability of chemicals by kernel partial least squares</article-title>. <source>J Comput Aided Chem</source>. <year>2009</year>;<volume>10</volume>:<fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr9-0092861512460759">
<label>9</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Tango</surname>
<given-names>T</given-names>
</name>
</person-group>. <source>Logistic Regression Analysis</source>. <publisher-loc>Tokyo, Japan</publisher-loc>: <publisher-name>Asakura Books</publisher-name>; <year>1996</year>.</citation>
</ref>
<ref id="bibr10-0092861512460759">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moineddin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Upshur</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Crighton</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mamdani</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Autoregression as a means of assessing the strength of seasonality in a time series</article-title>. <source>Popul Health Metr</source>. <year>2003</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr11-0092861512460759">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>King</surname>
<given-names>LM</given-names>
</name>
</person-group>. <article-title>Model selection using AIC in the presence of one-sided information</article-title>. <source>J Stat Plan Inference</source>. <year>2003</year>;<volume>115</volume>:<fpage>397</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr12-0092861512460759">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Zucoloto</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Erythema multiforme minor: a revision</article-title>. <source>Am J Infect Dis</source>. <year>2008</year>;<volume>4</volume>(<issue>4</issue>):<fpage>224</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr13-0092861512460759">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auquier-Dunant</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mockenhaupt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Naldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Crreia</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Roujeau</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study</article-title>. <source>Arch Dermatol</source>. <year>2002</year>;<volume>138</volume>(<issue>8</issue>):<fpage>1019</fpage>–<lpage>1024</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>